We have two main areas of interest:
International consortia, such as The Cancer Genome Atlas Network (TCGA) defined genomic, transcriptomic and epigenomic characteristics of glioblastoma, the most aggressive form of human brain tumors. Integrated analyses of OMICS data revealed that glioblastoma tumors segregate into molecular subgroups and may have different biological behaviors. However, these OMICS data had no direct utility in clinical diagnostics. Our research group selected the most important subgroup defining molecular markers from the TCGA results, and by using immunohistochemistry (IHC) and pyrosequencing, we tested these markers in clinical, formalin-fixed, paraffin-embedded (FFPE) glioblastoma specimens. These studies reproduced the molecular subtypes of these tumors, correlated clinical characteristics and opened new avenues for the identification of targetable molecular alterations in clinical specimens. Future analyses extend into deeper characterization of somatic genetic / genomic alterations accumulating within glioblastoma tumors and in molecular subtypes, in order to identify niches of molecular pathogenesis.
Working in a collaborating group, we are involved in the diagnostic work up of patients with rare neurological diseases. Representing a tertiary referral center, our core team is involved in the clinical work up of patients with rare neurological diseases. The team includes several clinical subspecialties such as a neurologist and molecular genetic researcher, pediatric neurologist, clinical geneticist and a neuropathologist relying on the services of several outside genetics labs. Together, we have identified a number of known pathogenic mutations inherited in the patients’ families, and are also aiming to discover new mutations in those patients who do not carry published genetic abnormalities. A better characterization of the disease phenotypes in correlation with the genotypes and exploring pathogenesis of neurological diseases are our main aims.
1. In the glioblastoma research project, we aim to generate a molecular marker panel with utility for supporting clinical prognostication and treatment decisions. In addition, we try to better understand the pathogenesis of this very malignant tumor, and to identify potential new treatment targets.
2. In the rare neurological disease studies, we aim to facilitate a better characterization of disease phenotypes and underlying genotypes driving pathogenesis, prepare for employing emerging molecular treatment modalities and support affected families.
TIOP 2.2.6 Molecular genetics part of an Oncology restructuring grant. Markusovszky University Hospital 2013.
University of Pecs, Award for Doctoral Dissertation (DSc degree). University of Pecs – one time award in December 2013.
Private donation - February 2015
University of Pecs Internal grant entitled “Support for innovative development” - December 2016